Yoda Therapeutics
Taipei, Taiwan· Est.
AI‑powered biotech developing disease‑modifying CNS therapies, with a Phase‑II orphan drug candidate for Multiple System Atrophy.
Is this your company? Claim your profile to update info and connect with investors.
Claim profilePrivate Company
Funding information not available
AI Company Overview
AI‑powered biotech developing disease‑modifying CNS therapies, with a Phase‑II orphan drug candidate for Multiple System Atrophy.
NeurologyNeurodegeneration
Technology Platform
AI‑driven drug discovery platform integrating multi‑omics data, molecular modeling, and predictive analytics to accelerate CNS target identification and candidate optimization.
Opportunities
AI‑enabled rapid discovery of CNS therapeutics and orphan‑drug designations provide pathways for accelerated approvals and strategic partnerships.
Risk Factors
High failure rates in CNS trials, reliance on AI predictions, and need for sustained financing pose significant challenges.
Competitive Landscape
Competes with AI biotech firms such as Insilico Medicine and Exscientia, differentiating through a dedicated focus on neurodegenerative and psychiatric disorders.